Head-to-head · WeighScore
Näky vs Tablet Health
The verdict
Näky takes it — 57.6/100 to 47.6/100.
Näky grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Näky is a LegitScript-approved telehealth platform offering compounded semaglutide and tirzepatide alongside an uncommon oral semaglutide drops product and a separate GLP-1 microdose program, plus NAD+ and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Näky | Tablet Health |
|---|---|---|
| WeighScore | 57.6/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #394 | #495 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #394 · C
Strengths
- LegitScript Approved (verifiable for benaky.com)
- Oral semaglutide drops as a distinct product line — uncommon among compounded GLP-1 brands
- Separate GLP-1 microdose program offered
- Adds NAD+ and Sermorelin for patients wanting a longevity stack
- 3-minute online assessment with a same-day treatment plan
Where it loses points
- Ongoing monthly pricing for compounded semaglutide and tirzepatide isn't shown until intake
- Oral semaglutide drops and microdose program pricing not disclosed
- Legal entity and state of incorporation not disclosed
- Pharmacy partner not named — only a generic 'USA-based FDA-regulated' claim
- States served not listed; pricing pages return 404s
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.